Immersive Virtual Reality to Improve Gait in Parkinson's Disease

NCT ID: NCT03727529

Last Updated: 2019-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). On the other hand, treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. The purpose of this single blinded randomized controlled trial is to study the effect of a combination of immersive virtual reality and treadmill walking on LRA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND

Parkinson's disease (PD) is the second most common degenerative neurological disease. PD induces gait disorders that lead to increased risk of falls. These falls seriously affect patients' quality of life and generate significant health care costs. Unfortunately, gait disorders do not respond well to drug treatments and their management is mainly based on rehabilitation treatment. The rehabilitation approach comprises two steps: a functional assessment of locomotor capacities followed by completion of a therapeutic physical exercise program.

Like heart rate, stride duration varies in the short and long term according to a complex dynamic of temporal variations. These variations present long-range autocorrelations (LRA): the stride duration does not vary randomly but in a structured way. The study of LRA is based on complex mathematical methods requiring recording of 512 consecutive gait cycles. LRA are altered in PD patients whose gait rhythm is excessively random. Alteration of LRA is correlated with neurological impairments (Hoehn \& Yahr scale and UPDRS) and patients' locomotor stability (ABC scale \& BESTest). Measurement of LRA would be the first available objective and quantitative biomarker of stability and risk of falling in patients with PD.

Guidelines concerning rehabilitation programs for PD patients are based on education (prevention of falls and inactivity,...), physical exercises, functional training (double task, complex tasks,...), learning, adaptation strategies (cueing) and action observation. The combination between immersive virtual reality (iVR) and treadmill walking will be developped.

Treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. A study carried out recently has shown that a single treadmill session reduces the stride duration variability during the intervention. There remains then to determine the long-term effect of this rehabilitation method on LRA, apart from the intervention, when walking overground. Combining iVR with treadmill walking rehabilitation offers interesting insights. Indeed, for stroke patients, this combination is more effective than classical techniques. For PD patients, non-immersive virtual reality methods (Wii, Kinect) have shown relative efficacy. Indeed, the use of non-immersive virtual reality on treadmill induces more efficient cognitive engagement and frontal lobe activation among PD patients. Non immersive VR gives longer-term effects and a greater decrease in the number of falls than without virtual reality. Furthermore, iVR makes it possible to give a functional character to reeducation and to enrich feedbacks. Indeed, iVR allows to give patients a visual flow when walking on treadmill as if they were walking overground and patients could benefit from it. But apart from a feasibility study, the therapeutic interest of iVR has not been studied yet for PD patients, especially iVR combined with treadmill walking. iVR is now easily accessible and its price is reduced, suggesting a potential for everyday clinical practice. Indeed, these new devices of good quality seem to have a good potential for neurorehabilitation. The purpose of this single blinded randomized controlled trial is then to study the effect of a comibination of immersive virtual reality and treadmill walking on LRA.

METHODS

Patients:

This study will be unicentric. 46 PD patients will be included, 23 in the intervention group and 23 in the control group. Patients will be recruited from the department of Neurology of Cliniques universitaires Saint-Luc (Brussels, Belgium). The study was approved by the local ethics committee. All patients will give informed written consent to the study. Eligibility criteria will be described in another section.

Functional assessment:

Functional assessments will cover the 3 domains of International Classification of Functioning, Disability and Health (ICF) : body functions and structures, activity and participation. Assessments will be described in another section.

LRA analysis:

At least 512 consecutive gait cycles will be recorded when walking overground at a self-selected speed on an oval track of 42 meters. The duration of each cycle will be measured using an accelerometer, placed on the head of the fibula, at an acquisition frequency of 512 Hz. LRA will be analyzed using the integrated method validated by our team for the analysis of physiological signals. This method combines calculation of the Hurst exponent (H) obtained by the Rescaled Range Analysis and the α exponent obtained by the Power Spectral Density Analysis. Consistency of the values of H and α is verified through the relation d = H-\[(1 + α) / 2\].

The presence of LRA can be shown with a high level of proof when these 3 conditions are met:

* H \> 0.5
* α is significantly different from 0 and less than 1
* d ≤ 0.10 If an inconsistency appears between H and α, the Randomly Shuffled Surrogate Data Test is applied in order to reject null hypothesis of an absence of temporal structure in studied series.

Procedure:

PD patients will follow a total of 18 treadmill exercise sessions with 3 sessions a week spread over 6 weeks. Sessions will be held at Cliniques universitaires Saint-Luc. During sessions, patients will walk 45 minutes at their comfortable speed on the treadmill with 1 pause allowed if necessary. The speed is determined according to the following technique: increase of the treadmill speed in increments of 0.10 m/s, with a starting speed of 0.15 m/s, until that the patient indicates that speed is too fast. Speed is then reduced by 0.10 m/s to have a comfortable walking speed. Every week, this walking speed will be re-evaluated. When walking on treadmill, patients will be secured with a harness (LiteGait, Mobility Research, Inc.).

Patients from the intervention group will wear a virtual reality headset while walking on the treadmill. Patients will walk in a straight line in a coherent, immersive and simple virtual environment created from a graphics software (Unity, USA). Before the first session, a 15-minute session will focus on patient familiarization with iVR.

Patients from the control group will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.

Statistical analyses:

To compare between the effect of the different treatments proposed by the two studies on LRA (primary outcome), a two-way repeated measures ANOVA (Group x Time) will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Gait Disorders, Neurologic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Group Type EXPERIMENTAL

Treadmill + VR

Intervention Type OTHER

Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR

Control group

Group Type ACTIVE_COMPARATOR

Treadmill

Intervention Type OTHER

Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treadmill + VR

Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR

Intervention Type OTHER

Treadmill

Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parkinson's Disease diagnosis made according to UK Brain Bank criteria
* Hoehn and Yahr score of 1 to 3 (physically independent, able to walk unassisted)
* Optimal drug treatment for at least 4 weeks at the time of inclusion
* In ON phase during assessments and treatment sessions

Exclusion Criteria

* Other pathologies that increase risk of falling
* Other pathologies that increase risk of nausea and vertigo
* Contraindication to physical exercising (ACSM criteria)
* Freezing of gait
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexis Lheureux, MD

Role: CONTACT

27645375 ext. +32

Thierry Lejeune, MD, PhD

Role: CONTACT

27641648 ext. +32

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexis Lheureux

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018/26MAR/132

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.